Related Experiment Video
Updated: Feb 22, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
14.4K
Rivaroxaban Use in Patients with Hemoglobinopathies
Chrysoula Apostolou1, Philippos Klonizakis1, Maria Mainou1
1a Adult Thalassemia Unit, Second Department of Internal Medicine , Aristotle University, Hippokration Hospital , Thessaloniki , Greece.
Hemoglobin
|September 28, 2017
Summary
Rivaroxaban showed promising safety and efficacy in eight patients with hemoglobinopathies experiencing thrombotic events. No bleeding or thrombotic complications occurred during follow-up, suggesting potential benefits for this population.
Area of Science:
- Hematology
- Cardiology
- Pharmacology
Background:
- Hemoglobinopathies present unique challenges for anticoagulation.
- Limited data exists on direct oral anticoagulant use in patients with hemoglobinopathies and thrombotic events.
Purpose of the Study:
- To evaluate the safety and efficacy of rivaroxaban in patients with hemoglobinopathies and a history of thrombotic events.
Main Methods:
- Retrospective case series of eight patients with hemoglobinopathies.
- Patients received rivaroxaban for stroke prevention (non-valvular atrial fibrillation) or deep vein thrombosis treatment.
- Follow-up duration ranged from 6 to 34 months.
Main Results:
- No thrombotic events were observed in any of the eight patients during the follow-up period.
- No bleeding events or other adverse events were reported.
- Rivaroxaban was well-tolerated in this small cohort.
Conclusions:
- Rivaroxaban appears to be a safe and effective option for managing thrombotic events in patients with hemoglobinopathies.
- Larger prospective studies are warranted to confirm these findings and establish definitive guidelines.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
01:29Venous Thrombosis III: Interprofessional Care
395
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
395
01:24Disorders of Hemostasis
2.4K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.4K
01:30Venous Thrombosis IV: Nursing Management
285
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
285
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
530
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
530